Rice Hall James & Associates LLC Sells 17,412 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Rice Hall James & Associates LLC lessened its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 10.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 147,037 shares of the company’s stock after selling 17,412 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Mirum Pharmaceuticals were worth $13,583,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Janus Henderson Group PLC grew its stake in Mirum Pharmaceuticals by 21.4% in the fourth quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after purchasing an additional 1,067,722 shares during the period. State Street Corp boosted its holdings in shares of Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after buying an additional 797,088 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Mirum Pharmaceuticals by 566.8% during the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after buying an additional 672,118 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Mirum Pharmaceuticals by 709.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock worth $44,889,000 after buying an additional 536,674 shares during the period. Finally, Voloridge Investment Management LLC grew its position in shares of Mirum Pharmaceuticals by 2,116.6% in the 3rd quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock worth $28,560,000 after buying an additional 371,999 shares during the period.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM opened at $113.03 on Friday. The business has a fifty day moving average price of $108.77 and a 200-day moving average price of $100.35. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. The company has a market capitalization of $6.89 billion, a PE ratio of -8.30 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 1-year low of $50.25 and a 1-year high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The firm had revenue of $159.88 million during the quarter, compared to the consensus estimate of $148.21 million. During the same quarter in the previous year, the firm earned ($0.30) EPS. The business’s revenue for the quarter was up 43.3% on a year-over-year basis. As a group, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $122.25, for a total value of $611,250.00. Following the completion of the transaction, the chief financial officer directly owned 42,181 shares of the company’s stock, valued at approximately $5,156,627.25. The trade was a 10.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares in the company, valued at approximately $18,622,574.56. This represents a 13.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 65,315 shares of company stock valued at $6,991,928. Insiders own 8.32% of the company’s stock.

Wall Street Analysts Forecast Growth

MIRM has been the subject of a number of recent research reports. Morgan Stanley lifted their price target on shares of Mirum Pharmaceuticals from $140.00 to $150.00 and gave the company an “overweight” rating in a research report on Thursday, June 11th. CLSA set a $146.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Wolfe Research began coverage on shares of Mirum Pharmaceuticals in a report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 target price for the company. Finally, Stifel Nicolaus set a $136.00 price target on Mirum Pharmaceuticals in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $143.40.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.